Radioactive main group and rare earth metals for imaging and therapy
TI Kostelnik, C Orvig - Chemical reviews, 2018 - ACS Publications
Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …
medicine with great success for several decades. The majority of current clinical use …
Somatostatin receptor antagonists for imaging and therapy
M Fani, GP Nicolas, D Wild - Journal of nuclear medicine, 2017 - Soc Nuclear Med
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have
been used for more than 20 y. An important improvement in recent years was the …
been used for more than 20 y. An important improvement in recent years was the …
Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective …
W Zhu, Y Cheng, X Wang, S Yao, C Bai… - Journal of Nuclear …, 2020 - Soc Nuclear Med
68Ga-DOTA-JR11 is a somatostatin receptor subtype 2–specific antagonist used for PET/CT
imaging. The purpose of this study was to compare 68Ga-DOTA-JR11 and 68Ga …
imaging. The purpose of this study was to compare 68Ga-DOTA-JR11 and 68Ga …
[HTML][HTML] The theranostic promise for Neuroendocrine Tumors in the late 2010s-Where do we stand, where do we go?
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept
of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors …
of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors …
[HTML][HTML] A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
Purpose We present the results of an open-label, phase I/II study evaluating the safety and
efficacy of the novel somatostatin receptor (SSTR) antagonist [177Lu] Lu-satoreotide …
efficacy of the novel somatostatin receptor (SSTR) antagonist [177Lu] Lu-satoreotide …
[HTML][HTML] Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
SB Schürrle, U Eberlein, C Ansquer… - European Journal of …, 2024 - Springer
Purpose To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled
somatostatin receptor antagonist [177Lu] Lu-satoreotide tetraxetan in patients with …
somatostatin receptor antagonist [177Lu] Lu-satoreotide tetraxetan in patients with …
Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim …
Z Lin, W Zhu, J Zhang, W Miao, S Yao… - Journal of Nuclear …, 2023 - Soc Nuclear Med
The current study aimed to compare 68Ga-NODAGA-Cpa-cyclo (d-Cys-amino-Phe-
hydroorotic acid-d-4-amino-Phe (carbamoyl)-Lys-Thr-Cys)-d-Tyr-NH2 (JR11) and 68Ga …
hydroorotic acid-d-4-amino-Phe (carbamoyl)-Lys-Thr-Cys)-d-Tyr-NH2 (JR11) and 68Ga …
Multimodal imaging of 2-cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an orthotopic neuroendocrine xenograft tumor mouse model
J Albrecht, S Exner, C Grötzinger… - Journal of nuclear …, 2021 - Soc Nuclear Med
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin receptor
(SSTR) analogs is a common approach in advanced neuroendocrine neoplasms. Recently …
(SSTR) analogs is a common approach in advanced neuroendocrine neoplasms. Recently …
Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects
ABSTRACT Introduction: Neuroendocrine tumors (NETs) harbor somatostatin receptors and
there is a strong rationale for using somatostatin analogs (SSAs) for treatment of NETs …
there is a strong rationale for using somatostatin analogs (SSAs) for treatment of NETs …
[HTML][HTML] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
G Santo, G Di Santo, I Virgolini - Seminars in Nuclear Medicine, 2024 - Elsevier
Peptide receptor radionuclide therapy (PRRT) today is a well-established treatment strategy
for patients with neuroendocrine tumors (NET). First performed already more than 30 years …
for patients with neuroendocrine tumors (NET). First performed already more than 30 years …